Background/Aims: The beneficial effects of omega-3 polyunsaturated fatty acids (n–3 PUFA) in the treatment of immunoglobulin A nephropathy (IgAN) have been reported. Perilla frutescens (Linn.) Britton var. frutescens is grown in Eastern Asia and its seed (perilla seed) is rich in α-linolenic acid, an n–3 PUFA. We investigated the antinephritic effects of perilla seed oil in a mouse model of IgAN. Methods: Ten-week-old high IgA ddY mice were fed diets containing either perilla seed oil (PS group) or corn oil (C group, control). After 20 weeks, we compared body weight, blood pressure, serum creatinine levels, IgA levels, fatty acid composition, urinary protein excretion, mesangial matrix expansion, and glomerular transforming growth factor-β1 mRNA expression between groups. Results: Serum n–3 PUFA levels were higher in the PS group than the C group (p < 0.001). Blood urea nitrogen levels were lower (p = 0.0246) and urinary protein excretion was reduced (p = 0.0198) in the PS group. Mesangial matrix expansion (p = 0.0063) and glomerular transforming growth factor-β1 mRNA expression (p = 0.0291) were suppressed in the PS group. No significant differences between groups were found in body weight, blood pressure, serum IgA, and creatinine levels. Conclusions: Dietary perilla seed oil supplement could suppress the progression of IgAN.

Journal Section:
Original Paper
Keywords:
High serum IgA mice, IgA nephropathy, Polyunsaturated fatty acids, Perilla frutescens, Transforming growth factor-β
1.
Emancipator SN, Lamm ME: IgA nephropathy: pathogenesis of the most common form of glomerulonephritis. Lab Invest 1989;60:168–183.
[PubMed]
2.
Chauveau D, Droz D: Follow-up evaluation of the first patients with IgA nephropathy described at Necker Hospital; in Bene MC, Faure G, Kesseler M (eds): IgA Nephropathy: The 25th Year. Contrib Nephrol. Basel, Karger, 1993, vol 104, pp 1–5.
3.
Tumlin JA, Madaio MP, Hennigar R: Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options. Clin J Am Soc Nephrol 2004;2:1054–1061.
https://doi.org/10.2215%2FCJN.04351206
4.
Chapkin RS, Kim W, Lupton JR, McMurray DN: Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids 2009;81:187–191.
https://doi.org/10.1016%2Fj.plefa.2009.05.010
5.
Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495–505.
[PubMed]
6.
Donadio JV Jr: Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin Proc 1991;66:1018–1028.
[PubMed]
7.
Miyawaki S, Muso E, Takeuchi E, Matsushima H, Shibata Y, Sasayama S, Yoshida H: Selective breeding for high serum IgA levels from noninbred ddY mice: isolation of a strain with an early onset of glomerular IgA deposition. Nephron 1997;76:201–207.
[PubMed]
https://doi.org/10.1159%2F000190169
8.
Muso E, Yoshida H, Takeuchi E, Yashiro M, Matsushima H, Oyama A, Suyama K, Kawamura T, Kamata T, Miyamaki S, Izui S, Sasayama S: Enhanced production of glomerular extracellular matrix in a new mouse strain of high serum IgA ddY mice. Kidney Int 1996;50:1946–1957.
[PubMed]
https://doi.org/10.1038%2Fki.1996.517
9.
Reeves PG, Nielsen FH, Fahey GC Jr: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939–1951.
[PubMed]
10.
Beli E, Li M, Cuff C, Pestka JJ: Docosahexaenoic acid-enriched fish oil consumption modulates immunoglobulin responses to and clearance of enteric reovirus infection in mice. J Nutr 2008;138:813–819.
11.
Jia Q, Zhou H-R, Bennink M, Pestka JJ: Docosahexaenoic acid attenuates mycotoxin-induced immunoglobulin a nephropathy, interleukin-6 transcription, and mitogen-activated protein kinase phosphorylation in mice. J Nutr 2004;134:3343–3349.
[PubMed]
12.
Grundt H, Nilsen DW, Hetland O, Mohammad MA: Clinical outcome and atherothrombogenic risk profile after prolonged wash-out following long-term treatment with high dose of n-3 PUFAs in patients with an acute myocardial infarction. Clin Nutr 2004;23:491–500.
https://doi.org/10.1016%2Fj.clnu.2003.09.005
13.
Mostad IL, Bjerve KS, Lydersen S, Grill V: Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes. Eur J Clin Nutr 2008;62:419–429.
https://doi.org/10.1038%2Fsj.ejcn.1602703
14.
Folch J, Lees M, Sloane-Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497–509.
[PubMed]
15.
Kuriki M, Asahi K, Asano K, Sakurai K, Eiro M, Suzuki H, Watanabe K, Katoh T, Watanabe T: Steroid therapy reduces mesangial matrix accumulation in advanced IgA nephropathy. Nephrol Dial Transplant 2003;18:1311–1315.
https://doi.org/10.1093%2Fndt%2Fgfg135
16.
Pestka JJ, Zhou H-R, Jia Q, Timmer AM: Dietary fish oil suppresses experimental immunoglobulin a nephropathy in mice. J Nutr 2002;132:261–269.
17.
Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H, Watanabe T: Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am J Kidney Dis 2005;45:288–294.
[PubMed]
https://doi.org/10.1053%2Fj.ajkd.2004.09.020
18.
Suzuki D, Miyata T, Nangaku M, Takano H, Saotome N, Toyoda M, Mori Y, Zhang SY, Inagi R, Endoh M, Kurokawa K, Sakai H: Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases. J Am Soc Nephrol 1999;10:2606–2613.
[PubMed]
19.
Toyoda M, Suzuki D, Zhang SY, Umezono T, Sakai H: In-situ hybridization studies of protein kinase Cα and β1 isoforms in human diabetic nephropathy. Clin Exp Nephrol 2001;5:250–256.
https://doi.org/10.1007%2Fs10157-001-8022-3
20.
Zhang SY, Suzuki D, Umezono T, Toyoda M, Sakai H: Expression of connective tissue growth factor mRNA in human IgA nephropathy. Clin Exp Nephrol 2001;5:33–39.
https://doi.org/10.1007%2Fs101570170029
21.
Radford MG Jr, Donadio JV Jr, Bergstralh EJ, Grande JP: Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8:199–207.
[PubMed]
22.
Morris MC, Sacks F, Rosner B: Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993;88:523–533.
[PubMed]
23.
Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ: Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002;20:1493–1499.
[PubMed]
https://doi.org/10.1097%2F00004872-200208000-00010
24.
Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE: A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994;331:1194–1199.
https://doi.org/10.1056%2FNEJM199411033311804
25.
Donadio JV, Grande JP: The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 2004;24:225–243.
https://doi.org/10.1016%2Fj.semnephrol.2004.01.004
26.
Donadio JV: The emerging role of omega-3 polyunsaturated fatty acids in the management of patients with IgA nephropathy. J Ren Nutr 2001;11:122–128.
https://doi.org/10.1053%2Fjren.2001.24355
27.
Uauy R, Mena P, Valenzuela A: Essential fatty acids as determinants of lipid requirements in infants, children and adults. Eur J Clin Nutr 1999;53(suppl 1):S66–S77.
[PubMed]
https://doi.org/10.1038%2Fsj.ejcn.1600745
28.
Fischer S, Weber PC: Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 1984;307:165–168.
https://doi.org/10.1038%2F307165a0
29.
Fischer S, Weber PC: Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5 omega 3). Biochem Biophys Res Commun 1983;116:1091–1099.
https://doi.org/10.1016%2FS0006-291X%2883%2980254-X
30.
Makino T, Ono T, Matsuyama K, Nogaki F, Miyawaki S, Honda G, Muso E: Suppressive effects of Perilla frutescens on IgA nephropathy in HIGA mice. Nephrol Dial Transplant 2003;18:484–490.
[PubMed]
https://doi.org/10.1093%2Fndt%2F18.3.484
31.
Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286–1292.
[PubMed]
https://doi.org/10.1056%2FNEJM199411103311907
32.
Okuda S, Languino LR, Ruoslahti E, Border WA: Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990;86:453–462.
[PubMed]
https://doi.org/10.1172%2FJCI114731
33.
Roberts AB, McCune BK, Sporn MB: TGF-beta: regulation of extracelluar matrix. Kidney Int 1992;41:557–559.
[PubMed]
https://doi.org/10.1038%2Fki.1992.81
34.
An WS, Kim HJ, Cho K-H, Vaziri ND: Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol 2009;297:F895–F903.
[PubMed]
https://doi.org/10.1152%2Fajprenal.00217.2009
35.
Garman JH, Mulroney S, Manigrasso M, Flynn E, Maric C: Omega-3 fatty acid rich diet prevents diabetic renal disease. Am J Physiol Renal Physiol 2009;296:F306–F316.
https://doi.org/10.1152%2Fajprenal.90326.2008
36.
Nakayama M, Fukuda N, Watanabe Y, Soma M, Hu WY, Kishioka H, Satoh C, Kubo A, Kanmatsuse K: Low dose of eicosapentaenoic acid inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats through suppression of transforming growth factor-beta. J Hypretens 1999;17:1421–1430.
https://doi.org/10.1097%2F00004872-199917100-00009
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.